NASDAQ
1.62USD
-0.11 (-6.36%)
We have scored 24 news catalysts on Skye Bioscience, Inc. (SKYE) over the past 12 months. The biggest single-day move next to one of them came Jan 7, 2026, when SKYE closed +9.9%: “SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit”. Coverage across the window leans negative (average ticker sentiment −0.78). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
7.1M
P/E
—
EPS
—
Beta
2.86
52W range
1.5-14.512
Day range
1.62–1.74
Open
1.74
Prev close
1.73
Volume
30.8K
Avg volume
287.8K
Dividend
0.00
IPO
2015-01-06
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Skye Bioscience, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SKYE: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
